Drug intelligence / Profile preview

CC-486 and Nivolumab Combination

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Vaccines & Immunotherapeutics
Administration: Oral

Overview

CC-486 is an oral form of azacitidine, a demethylation agent that helps bone marrow produce normal blood cells and kills abnormal cells. Nivolumab (Opdivo) is an immune checkpoint inhibitor that targets PD-1 receptors. This combination therapy is being investigated as a treatment for Hodgkin lymphoma, particularly in cases refractory to PD-1 blockade. It has shown promising results in clinical trials with a favorable safety profile.

Targets

PDCD1 (Programmed cell death protein 1 receptor)DNMT (DNA methyltransferase)

Beyond the preview

Go deeper on CC-486 and Nivolumab Combination.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CC-486 and Nivolumab Combination.

Explore the full profile